Literature DB >> 9790510

Selective deletion of exon 1 beta of the p19ARF gene in metastatic melanoma cell lines.

R Kumar1, I Sauroja, K Punnonen, C Jansen, K Hemminki.   

Abstract

The INK4A locus on 9p21 is deleted or rearranged in a large number of human cancers. The locus encodes two unrelated and independently acting negative cell-cycle regulators, p16 and p19ARF, arising in alternate reading frames from a partly shared sequence. We analyzed five human melanoma cell lines for deletions at the INK4 loci and flanking microsatellite markers on 9p21. All the cell lines displayed deletions of varying sizes. The metastatic cell line IGR-1 showed a large deletion between the markers D9S736 and D9S171. In the cell lines WM-115 and WM-266-4, the deletion included exon 1alpha of p16, exon 1beta of p19ARF, and exon 2 of the INK4B (p15) gene. Two cell lines, SK-MEL-5 and A2058, had deletions confined to exon 1beta and the microsatellite marker D9S942. RT-PCR experiments showed the presence of the p16 and p15 transcripts and absence of p19ARF expression in both SK-MEL-5 and A2058 cell lines. The selective loss of the exon 1beta of p19ARF and retention of the p16 and p15 genes and their expressions in these two cell lines support the putative tumor suppressor role for the alternate reading frame p19ARF gene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790510     DOI: 10.1002/(sici)1098-2264(199811)23:3<273::aid-gcc11>3.0.co;2-n

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

1.  Similar nucleotide excision repair capacity in melanocytes and melanoma cells.

Authors:  Shobhan Gaddameedhi; Michael G Kemp; Joyce T Reardon; Janiel M Shields; Stephanie L Smith-Roe; William K Kaufmann; Aziz Sancar
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  ARF mutation accelerates pituitary tumor development in Rb+/- mice.

Authors:  Kenneth Y Tsai; David MacPherson; Douglas A Rubinson; Alexander Yu Nikitin; Roderick Bronson; Kim L Mercer; Denise Crowley; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-16       Impact factor: 11.205

3.  Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification.

Authors:  Joanne S Aveyard; Margaret A Knowles
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

4.  Informing patients about their mutation tests: CDKN2A c.256G>A in melanoma as an example.

Authors:  Kari Hemminki; Aayushi Srivastava; Sivaramakrishna Rachakonda; Obul Bandapalli; Eduardo Nagore; Akseli Hemminki; Rajiv Kumar
Journal:  Hered Cancer Clin Pract       Date:  2020-07-31       Impact factor: 2.857

5.  Immortalization of human mammary epithelial cells is associated with inactivation of the p14ARF-p53 pathway.

Authors:  Vladimir A Shamanin; Elliot J Androphy
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

6.  Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.

Authors:  F Xing; Y Persaud; C A Pratilas; B S Taylor; M Janakiraman; Q-B She; H Gallardo; C Liu; T Merghoub; B Hefter; I Dolgalev; A Viale; A Heguy; E De Stanchina; D Cobrinik; G Bollag; J Wolchok; A Houghton; D B Solit
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

7.  Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.

Authors:  N Soufir; B Bressac-de Paillerets; L Desjardins; C Lévy; J Bombled; I Gorin; P Schlienger; D Stoppa-Lyonnet
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

8.  Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts.

Authors:  Huaping Xie; P Sivaramakrishna Rachakonda; Barbara Heidenreich; Eduardo Nagore; Antje Sucker; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  Oncotarget       Date:  2016-03-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.